Risk Factors for Long-Term Contracture Recurrence after Collagenase Injection for Dupuytren Disease : A Prospective Cohort Study
(2023) In Biomedicines 11(3).- Abstract
In Dupuytren disease, little is known about the long-term outcomes of collagenase injection or risk factors for contracture recurrence. In this prospective study, 159 patients (242 fingers) with Dupuytren disease and active extension deficit (AED) ≥20° in a metacarpophalangeal (MCP) or proximal interphalangeal (PIP) joint were treated with collagenase injection during a 14-month period. At 5 years, 18 patients were deceased, 2 could not be contacted, and 13 had undergone fasciectomy. The remaining 126 patients (199 treated fingers) participated in a follow-up evaluation at 52–96 (mean 65) months after injection, with physical examination (114 patients) or telephone interview (12 patients). Recurrence was defined as subsequent treatment... (More)
In Dupuytren disease, little is known about the long-term outcomes of collagenase injection or risk factors for contracture recurrence. In this prospective study, 159 patients (242 fingers) with Dupuytren disease and active extension deficit (AED) ≥20° in a metacarpophalangeal (MCP) or proximal interphalangeal (PIP) joint were treated with collagenase injection during a 14-month period. At 5 years, 18 patients were deceased, 2 could not be contacted, and 13 had undergone fasciectomy. The remaining 126 patients (199 treated fingers) participated in a follow-up evaluation at 52–96 (mean 65) months after injection, with physical examination (114 patients) or telephone interview (12 patients). Recurrence was defined as subsequent treatment (surgery or repeat injection) or ≥20° AED worsening in a treated joint between the 6-week and 5-year measurements. The mean AED at baseline was 42° (SD 24) for MCP joints and 31° (SD 29) for PIP joints and at 5 years 11° (SD 17) and 17° (SD 23), respectively. Recurrence occurred in 17% of MCP joints and 25% of PIP joints. Statistically significant risk factors for PIP joint contracture recurrence were greater baseline AED (odds ratio 1.04, 95% CI 1.02–1.06) and small finger treatment (OR 4.6, 95% CI 1.5–14.3), with no significant risk factors found for MCP contracture recurrence.
(Less)
- author
- Eckerdal, David LU ; Lauritzson, Anna ; Åkesson, Anna and Atroshi, Isam LU
- organization
- publishing date
- 2023-03
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- collagenase, contracture, Dupuytren, recurrence
- in
- Biomedicines
- volume
- 11
- issue
- 3
- article number
- 699
- publisher
- MDPI AG
- external identifiers
-
- pmid:36979678
- scopus:85151959839
- ISSN
- 2227-9059
- DOI
- 10.3390/biomedicines11030699
- language
- English
- LU publication?
- yes
- id
- 7363c2a9-6356-415a-9f1f-b95cb93f1aba
- date added to LUP
- 2023-09-22 12:23:36
- date last changed
- 2024-04-19 01:32:06
@article{7363c2a9-6356-415a-9f1f-b95cb93f1aba, abstract = {{<p>In Dupuytren disease, little is known about the long-term outcomes of collagenase injection or risk factors for contracture recurrence. In this prospective study, 159 patients (242 fingers) with Dupuytren disease and active extension deficit (AED) ≥20° in a metacarpophalangeal (MCP) or proximal interphalangeal (PIP) joint were treated with collagenase injection during a 14-month period. At 5 years, 18 patients were deceased, 2 could not be contacted, and 13 had undergone fasciectomy. The remaining 126 patients (199 treated fingers) participated in a follow-up evaluation at 52–96 (mean 65) months after injection, with physical examination (114 patients) or telephone interview (12 patients). Recurrence was defined as subsequent treatment (surgery or repeat injection) or ≥20° AED worsening in a treated joint between the 6-week and 5-year measurements. The mean AED at baseline was 42° (SD 24) for MCP joints and 31° (SD 29) for PIP joints and at 5 years 11° (SD 17) and 17° (SD 23), respectively. Recurrence occurred in 17% of MCP joints and 25% of PIP joints. Statistically significant risk factors for PIP joint contracture recurrence were greater baseline AED (odds ratio 1.04, 95% CI 1.02–1.06) and small finger treatment (OR 4.6, 95% CI 1.5–14.3), with no significant risk factors found for MCP contracture recurrence.</p>}}, author = {{Eckerdal, David and Lauritzson, Anna and Åkesson, Anna and Atroshi, Isam}}, issn = {{2227-9059}}, keywords = {{collagenase; contracture; Dupuytren; recurrence}}, language = {{eng}}, number = {{3}}, publisher = {{MDPI AG}}, series = {{Biomedicines}}, title = {{Risk Factors for Long-Term Contracture Recurrence after Collagenase Injection for Dupuytren Disease : A Prospective Cohort Study}}, url = {{http://dx.doi.org/10.3390/biomedicines11030699}}, doi = {{10.3390/biomedicines11030699}}, volume = {{11}}, year = {{2023}}, }